Clonal hematopoiesis screening in patients receiving cytotoxic chemotherapy

Описание: Koichi Takahashi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the standardization of clonal hematopoiesis screening for patients receiving cytotoxic chemotherapy, to identify those at high risk of developing therapy-related acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Dr Takahashi suggests that screening should be considered for high-risk populations, but is opposed to widespread screening for all cancer patients. This interview took place at the 7th International Workshop on Acute Leukemias (iwAL 2025), held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.